Michele Simmons Redell, MD, PhD
- Texas Medical Center
Associate Professor, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine
|Baylor College of Medicine||fellowship||Pediatric Hematology/Oncology||2004|
|Baylor College of Medicine||residency||Pediatrics||2001|
|University of Washington||medical school||Doctor of Medicine||1998|
|University of Washington||postgraduate education||Doctor of Philosophy||1996|
Dr. Michele Redell is a member of the Leukemia Team at Texas Children’s Cancer and Hematology Centers. She sees patients with leukemia in the clinic one day a week, and she supervises residents and fellows in the outpatient setting, as well.
Dr. Redell is the local Principal Investigator for the Children’s Oncology Group clinical trial for patients who are newly diagnosed with acute myeloid leukemia (AAML1031). Dr. Redell serves a number of roles within the Children’s Oncology Group AML committee, including membership on the Steering Committee and Vice Chair of Biology. She is member of the study committees for two COG clinical trials, including the upcoming therapeutic trial for children with Down Syndrome and AML (AAML1531), and the new registry and biology protocol known as Project:EveryChild (APEC14B1).
American Board of Pediatrics
American Board of Pediatrics-Hematology/Oncology
|American Academy of Pediatrics (AAP)||Member|
|American Society of Hematology (ASH)||Member|
|American Society of Pediatric Hematology-Oncology (ASPHO)||Member|
Dr. Michele Redell is a member of the leukemia team and lymphoma team. Dr. Michele Redell is also conducting research under the mentorship of Dr. David Tweardy, Chief of the Section of Infectious Diseases at Baylor College of Medicine. She is interested in understanding the molecular steps that determine whether an immature cell in the bone marrow becomes a normal mature neutrophil or a malignant leukemia cell. Dr. Michele Redell is focusing on a signaling protein known as Stat3, which has two main variants and is activated in response to cytokines that control myeloid cell survival, proliferation, and maturation. She is investigating the distinct roles of the Stat3 variants in normal neutrophil development in mice. Stat3 is also known to be an important protein in many kinds of cancer, including acute myeloid leukemia (AML). Dr. Michele Redell is studying the mechanisms by which Stat3 becomes inappropriately activated in AML. With Dr. Tweardy, she is working with new agents that can block Stat3, to test their potential effectiveness as novel therapies for cancers including AML.